HIGHLIGHTS from SABCS: Opposite Effects on Breast Cancer Incidence with Estrogen and Estrogen Plus Progestin

HIGHLIGHTS from SABCS: Identification of mechanisms driving acquired chemoresistance in preclinical models of taxane resistance.

HIGHLIGHTS from SABCS: Addition of S-1 to Post-operative Endocrine Therapy Improves Outcomes for Patients with Hormone Receptor-positive, HER2-negative Breast Cancer

HIGHLIGHTS from SABCS: New HER2 Antibody-drug Conjugate Yielded Promising Clinical Responses in Breast Cancer Patients Pre-treated with T-DM1

HIGHLIGHTS from SABCS: Phase III SOPHIA study: HER2+metastatic breast cancer interim overall survival analysis